Dalcetrapib

WikiDoc Resources for Dalcetrapib
Articles
Most recent articles on Dalcetrapib Most cited articles on Dalcetrapib Review articles on Dalcetrapib Articles on Dalcetrapib in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dalcetrapib Images of Dalcetrapib Photos of Dalcetrapib Podcasts & MP3s on Dalcetrapib Videos on Dalcetrapib
Evidence Based Medicine
Cochrane Collaboration on Dalcetrapib Bandolier on Dalcetrapib TRIP on Dalcetrapib
Clinical Trials
Ongoing Trials on Dalcetrapib at Clinical Trials.gov Trial results on Dalcetrapib Clinical Trials on Dalcetrapib at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dalcetrapib NICE Guidance on Dalcetrapib NHS PRODIGY Guidance FDA on Dalcetrapib CDC on Dalcetrapib
Books
Books on Dalcetrapib
News
Dalcetrapib in the news Be alerted to news on Dalcetrapib News trends on Dalcetrapib
Commentary
Blogs on Dalcetrapib
Definitions
Definitions of Dalcetrapib
Patient Resources / Community
Patient resources on Dalcetrapib Discussion groups on Dalcetrapib Patient Handouts on Dalcetrapib Directions to Hospitals Treating Dalcetrapib Risk calculators and risk factors for Dalcetrapib
Healthcare Provider Resources
Symptoms of Dalcetrapib Causes & Risk Factors for Dalcetrapib Diagnostic studies for Dalcetrapib Treatment of Dalcetrapib
Continuing Medical Education (CME)
CME Programs on Dalcetrapib
International
Dalcetrapib en Espanol Dalcetrapib en Francais
Business
Dalcetrapib in the Marketplace Patents on Dalcetrapib
Experimental / Informatics
List of terms related to Dalcetrapib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Dalcetrapib or JTT-705 is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health.

A 24 week clinical trial showed that dalcetrapib did increase HDL-C levels, supporting the agent's desired effect. Further, the dal-PLAQUE phase IIb trial found evidence of plaque reduction. Plaque reduction is an anticipated observation following an increase in HDL.

As of 2010 five phase II trials had started and there was no evidence of the raised blood pressure seen with torcetrapib.

dal-VESSEL phase IIb trial found no evidence of flow-mediated dilatation improvement. A 17% increase of Lp-PLA₂ mass level was noted. Lp-PLA₂ is associated with coronary heart disease and stroke.

dal-OUTCOMES phase III trial passed its first interim review in July, 2011, however, development was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy”. The results of dal-OUTCOMES III were published in November, 2012.